drugset / Trial / NCT02202005

Multiple Dose BE Study With Nevirapine 400mg PR Tablets

NCT02202005

Phase 1 Completed 46 enrolled Ratiopharm GmbH
Non-randomizedCrossoverOpen-label

Summary

The objective of this steady state pivotal study is to compare the rate and extent of absorption and to evaluate Bioequivalence of test drug compared to the approved reference product in HIV infected individuals

Timeline

Start
2014-08
Primary completion
2015-07
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Nevirapine Small molecule 400 mg

Indications

No indication recorded.